The major acute complications of CD19 CAR T cell therapies are cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and macrophage activation syndrome (MAS) originating from T cell activation and proliferation with excessive secretion of cytokines and triggering of an immune activation cascade [3]. This evidence concerns the gene CD19 and macrophage activation syndrome.